Urology Strong — NICE NG131 / EAU 2023
Prostate Cancer Risk Stratification (NICE / EAU)
Risk stratification for localised/locally advanced prostate cancer using PSA, Gleason grade group, and clinical stage to guide treatment planning.
References
- NICE NG131. Prostate cancer: diagnosis and management. 2019 (updated 2021).
- EAU Guidelines on Prostate Cancer. 2023.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Gleason Score / Grade Group for Prostate Cancer · Prostate Cancer
- UCSF-CAPRA Score for Prostate Cancer · Prostate Cancer
- PSA Doubling Time (PSADT) Calculator · Prostate Cancer
- D'Amico Risk Classification for Prostate Cancer · Prostate Cancer
- PSA Velocity and PSA Density · Prostate Cancer
- D'Amico Risk Stratification for Localised Prostate Cancer · Prostate Cancer
Drugs
- Alfacalcidol (1-alpha-Hydroxycholecalciferol) · Active Vitamin D Analogue
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Folic Acid · Vitamin B group (folate)
- Levofolinic acid (calcium levofolinate) · Reduced folate (active enantiomer of folinic acid)
- Meningococcal group B vaccine · Vaccine
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.